Introduction
The proto-oncogene c-MYC, discovered over a quarter of a century ago as the cellular homolog of the oncogene associated with several avian retroviruses, has a pivotal function in growth control, differentiation and apoptosis and is among the most frequently affected genes in human cancers. It is overexpressed in a large percentage of human tumors, including cancers of lymphoid, mesenchymal and epithelial origin (Evan and Littlewood, 1993; Henriksson and Luscher, 1996) . The transcription factor c-MYC orchestrates the expression of 10% to more than 15% of all cellular genes, employing many technologies including high-throughput screens (Knoepfler, 2007) . MYC target genes participate in cell cycle, survival, protein synthesis, cell adhesion and cytoskeleton and metabolism, and Micro-RNA expression is also part of the repertoire of its regulated transcripts (Dang et al., 2006) . Different target genes are regulated under specific conditions for specific cell types. Yet, the downstream c-MYC targets responsible for physiological compared with tumorigenic functions have not been distinguished (Dang et al., 2006) . The expression of c-MYC protein is deregulated in human cancers by a number of different mechanisms (Spencer and Groudine, 1991) , including chromosomal translocations and amplifications, activation of upstream growth stimulatory signaling cascades and increased protein stability.
In addition to its function in driving the cell cycle and in cell transformation, over 15 years ago, c-MYC was also shown to participate in the apoptotic response (Askew et al., 1991; Evan et al., 1992; Shi et al., 1992) . It can either induce or sensitize cells to apoptosis, demonstrated in interleukin (IL)-3-dependent 32Dcl3 myeloid progenitor cells. Following IL-3 withdrawal, c-MYC is downregulated and cells become growth arrested, accumulating in the G0/G1 phase of the cell cycle, and rapidly undergo apoptosis. Enforced c-MYC expression accelerates the apoptotic response in the absence of IL-3 (Askew et al., 1991) . In addition, when 32Dcl3 cells are cultured to high density in the presence of IL-3, the cells undergo growth arrest, maintain viability and c-MYC is downregulated; however, when c-MYC expression is deregulated, the cells die by apoptosis. This indicates that IL-3 cannot protect the cells (Askew et al., 1993) . Induction of apoptosis by deregulated c-MYC was also observed both in the Rat-1 fibroblast cell line and primary rat embryo fibroblasts deprived of serum, as well as in Rat-1 fibroblasts growth arrested by either a thymidine block or isoleucine starvation (Evan et al., 1992) . The extent of the apoptotic response is correlated with the level of MYC expression, where the level of MYC expression similar to the level in untransformed cells is sufficient to induce apoptosis (Evan et al., 1992) .
MYC-triggered apoptosis provides a built-in failsafe program to limit unchecked cell growth under inappropriate conditions, ensuring that it is restricted to the correct environment. This failsafe program, also a property of oncogenes E1A and E2F-1, controls tumor growth and progression. Tumors from cells overexpressing c-MYC often have mutations that disable the apoptotic program. In the past 15 years, research on apoptosis and the involvement of the c-MYC protooncogene has been extensive Meyer et al., 2006; Nieminen et al., 2007a) . The ramifications with regard to tumor etiology and progression, as well as the response of malignancies to different therapies, have been tremendously enhanced by many of these studies, involving the identification of targets involved in the MYC-triggered apoptotic response and on the flip side, identifying which apoptotic regulators are disabled in tumor cells. Many questions still remain to be answered. This article will provide an overview of the function of the tumor suppressor gene product p53 in the c-MYCmediated apoptotic response, and how c-MYC amplifies the intrinsic mitochondrial pathway and triggers and/or amplifies the death receptor pathways. Finally, a model for how deregulated c-MYC prematurely triggers the normal apoptotic response associated with terminal myeloid differentiation while also blocking the differentiation program will be presented.
The c-MYC protein and its network of interacting partners
The c-MYC protein is a transcription factor that both activates and represses target genes, using several mechanisms including recruitment of histone acetylases, chromatin modulating proteins, basal transcription factors and DNA methyltransferases (Dang et al., 2006) . It is a basic-helix-loop-helix-leucine zipper protein, where its carboxy terminus contains three structural domains (Hoffman and Liebermann, 1998; Nilsson and Cleveland, 2003) . These include the HLH and Zip motifs that promote protein-protein interaction, and the basic region mediates sequence-specific DNA binding. The amino terminus contains four domains referred to as MYC homology boxes I, II, III and IV. In-depth structure-function analysis has shown that MYC box 1 (MBI) has an important function in protein stability and MYC box 2 (MBII) is required for transcriptional activation and repression, which have been shown to be uncoupled experimentally (Oster et al., 2002 (Oster et al., , 2003 . These studies, as well as others, suggested a close association of c-MYC target gene repression and apoptosis (Conzen et al., 2000; Oster et al., 2003) . It should be noted that apoptosis was assessed following serum starvation of fibroblasts. Interestingly, the apoptotic response has been shown to require upregulation of multiple gene products, as shown in this article, so repression may be necessary but not sufficient for apoptosis. In addition, target genes may vary with different cell types and distinct apoptotic stimuli. A constant theme about how c-MYC modulates apoptosis is the variability of ways that c-MYC influences the apoptotic process; many regulators of apoptosis are affected by c-MYC overexpression.
c-MYC functions as a transcriptional regulator as part of a network of interacting factors (Eisenman, 2000; Baudino and Cleveland, 2001; Luscher, 2001; Hurlin and Huang, 2006; Rottman and Luscher, 2006) . Under physiological conditions, c-MYC cannot form homodimers, but rather binds to Max, a ubiquitous bHLHZip protein that is an obligate heterodimeric partner for c-MYC in mediating its functions. Initially, two additional partners for Max had been identified, Mxi1 and Mad. Two more Max-interacting proteins, Mad3 and Mad4, which behave similarly to Mad (Mad1), have been reported. It has been proposed that transcription activation is mediated exclusively by MYC-Max complexes, whereas Max-Max, Max-Mad and Max-Mxi complexes mediate transcription repression through identical binding sites. Max expression is not highly regulated and its protein is very stable; in contrast, Mad protein appears to have a short half-life and to be highly regulated (Amati and Land, 1994) . Mxi protein is also regulated; however, substantial amounts are already present in many undifferentiated cell types (Amati and Land, 1994) . Other Max-interacting partners include the larger proteins, Mnt and Mga. Mnt is coexpressed with c-MYC, yet mediates repression of expression.
The Max-containing heterodimers associate with larger complexes, depending upon the partner protein, resulting in either recruitment or displacement of the basal transcriptional machinery. MYC-Max heterodimers activate transcription through interactions with transcriptional coactivators (that is, TRRAP, BAF53) and their associated histone acetyltransferases and/or ATPase/helicases . The Mnt-Max or Mad-Max heterodimers form a ternary complex with the general transcription corepressors mSin3A and mSin3B and participate in transcriptional repression (Eisenman, 2000; Baudino and Cleveland, 2001; Luscher, 2001; Hurlin and Huang, 2006; Rottman and Luscher, 2006) ; this repression is a consequence of the association of Sin3 with multiprotein complexes including co-repressors (that is, e N-Cor, Ski/Sno) and histone deacetylases. Another layer of complexity has emerged from the binding of MYC-Max dimers to, and disrupting the functions of, other transcriptional activators, thereby repressing transcription. For example, c-MYC negatively regulates p21/CIP by binding to and inhibiting the transcriptional activator Miz-1 (Wu et al., 2003) . There is a c-MYC responsive region in the p21 core promoter, and c-MYC was shown to bind to this region in vitro and in vivo through interaction with the initiator-binding Zn-finger transcription factor Miz-1. Miz1 associates directly with the promoter. Association of c-MYC with the promoter in vivo correlates inversely with p21 expression. Finally, using mutants of c-MYC with impaired binding to Miz-1, it was shown that repression of p21 promoter/reporters and endogenous p21 depends on the interaction of c-MYC with Miz-1 (Wu et al., 2003) .
Manipulating the expression of the different members of the MYC network of proteins established their individual functions. It has been established that Max is esssential for c-MYC-mediated gene transactivation, transformation, cell cycle progression and apoptosis . Overexpression of Max c-MYC in apoptosis and cancer B Hoffman and DA Liebermann in transgenic mice (Eu-myc/Eu-max) also overexpressing c-MYC reduced the rate of lymphoma onset compared with Eu-myc transgenic mice, suggesting that elevation of Max expression in vivo inhibits the function of c-MYC (Adams et al., 1985 (Adams et al., , 1999 . Overexpression of Mxi1 (or Mxi-SR) and Mad can antagonize c-MYC activity in cellular transformation assays and proliferation and can diminish the malignant phenotype of tumor cells. Mad1 can also inhibit apoptosis and reverse the differentiation blocking effect of c-MYC in erythroleukemia cells. These findings are consistent with the notion that Mad and Mxi1 suppress c-MYC function (Amati and Land, 1994; Luscher, 2001) .
In addition to interacting with proteins involved in transcription regulation, c-MYC also interacts with enzymes controlling histone methylation (Luscher and Larsson, 2007) . MYC also seems to have a global effect on chromatin structure; overall, histone acetylation decreases and methylation is altered in neuronal cells in response to disrupution of MycN (Knoepfler, 2007) .
Cross talk between MYC and p53 in regulating cell survival and apoptosis Apoptosis triggered or sensitized by c-MYC can be either p53-dependent or p53-independent, determined by the cell type and apoptotic trigger. The p53 tumor suppressor is a major mediator of cell-cycle arrest and/or apoptosis in the response of mammalian cells to stress stimuli and is often referred to as the guardian of the genome. p53 protein is expressed at low levels in cells at all times and is elevated in response to stress. The ARFMdm2 (mouse double minute-2)-p53 regulatory loop controls the level of p53 protein. Mdm2 is a negative regulator of p53, ultimately causing p53 degradation by the proteasome, whereas p53 transcriptionally upregulates Mdm2. ARF inhibits Mdm2 function. MYC activation leads to increased ARF expression (Zindy et al., 1998) , resulting in increased p53 protein. FoxO transcription factors have been shown to mediate MYCinduced ARF expression, binding to the Ink4a/Arf locus and activating its expression ( Figure 1a ; Bouchard et al., 2007) . ARF negatively regulates the transcriptional activity of MYC by associating with and relocating MYC from the nucleoplasm to the nucleolus (Amente et al., 2006; Meyer et al., 2006; Sarker and Fisher, 2006) , interacting with the MYC-Max complex through the MYC Box II domain. Thus, ARF is a negative regulator of MYC, consistent with ARF having a p53-independent growth suppressive function.
The consequences of ARF inactivation have been widely studied in Em-myc transgenic mice in which c-MYC, regulated by the immunoglobulin heavy chain enhancer-promoter, is expressed in B lymphocytes. Within their first year of life, Em-myc transgenic mice develop malignant monoclonal lymphomas (mean latency of 25 weeks). Biallelic loss of ARF occurs in approximately 25% of these animals, whereas another 33% display p53 mutations. Arf -/-Em-myc mice are even more prone to lymphoma development and die of aggressive lympholeukemias as early as 4-7 weeks of age (Adams et al., 1985; Eischen et al., 1999; Schmitt et al., 1999) .
The ataxia-telangiectasia-mutated (ATM) kinase, a major regulator of the cellular response to DNA doublestrand breaks, also regulates p53 protein levels. In the absence of ATM, p53 accumulation and phosphorylation are greatly reduced, and it has been recently shown that ATM is critical for p53 activation and the induction of apoptosis in response to c-MYC, suggesting that, in at least some cases, the ARF and ATM pathways cooperate with c-MYC to activate p53 and promote apoptosis ( Figure 1a ; Pusapati et al., 2006) . Furthermore, inhibition of ATM/ATR kinases abolishes both induction of Rad51 and phosphorylation of p53 and reduced the level of apoptosis induced by coexpression of oncogenes and ARF (Pauklin et al., 2005) . It should be noted that c-MYC overexpression, a common event in human cancers, causes DNA damage in vivo and could contribute to the activation of the ATM signaling pathway that is observed in early-stage clinical specimens (Sargent et al., 1996; Felsher and Bishop, 1999; Vafa et al., 2002; Pusapati et al., 2006) . p53 can cause either growth arrest or apoptosis, and the choice involves a complex interplay of numerous factors. p53 activation is accompanied by downregulation of c-MYC expression and growth arrest (Guillouf et al., 1995) . It has been shown that c-MYC expression is transcriptionally repressed by p53, where p53 is bound to the c-MYC promoter and there is a decrease in the level of acetlylated histone H4 at the c-MYC promoter (Ho et al., 2005) . Deregulated expression of c-MYC abrogates p53-mediated growth arrest. In contrast to p53, the proto-oncogene c-MYC promotes either apoptosis or cell-cycle progression. In addition to repressing transcription of c-MYC, p53 induces expression of the cyclin-dependent kinase inhibitor p21, a major mediator of p53-induced G1 growth arrest. The c-MYC in apoptosis and cancer B Hoffman and DA Liebermann gadd45a gene is another p53 target implicated in mediating growth arrest (Guillouf et al., 1995; Liebermann and Hoffman, 2002) . The mechanism through which gadd45a elicits G1 growth arrest is not fully understood; however, it was shown that Gadd45a associates with p21. Therefore, it is possible that interaction of Gadd45a with p21 serves to augment the cyclin-dependent kinase inhibitor activity of p21, and the function of Gadd45a in growth arrest would be mediated through p21 (Vairapandi et al., 1996; Liebermann and Hoffman, 2002) . Interestingly, c-MYC expression downregulates both p21 and gadd45a expression as well as other growth arrest genes including gas1, p15, p27, gadd34 and gadd153 (Amundson et al., 1998; Seoane et al., 2002; Gartel and Shchors, 2003; Wu et al., 2003) . c-MYC was shown to be directly recruited to the p21(Cip1) promoter by the DNA-binding protein Miz-1, blocking p21(Cip1) induction by p53 (Seoane et al., 2002; Wu et al., 2003) . By inhibiting p21(Cip1), c-MYC influences the outcome of a p53 response in favor of cell death (Vousden, 2002; Figure 1b) . Although c-MYC represses growth arrest genes that are positively regulated by p53, MYC has no effect on p53-regulated target genes that promote apoptosis; in fact, both transcription factors activate many of the same target genes. Clearly, the level of p53 and c-MYC should determine if gadd45a and p21 are induced or suppressed, and if cells undergo apoptosis or growth arrest.
In cells where DNA damage results in the p53-mediated apoptotic response, it was observed that DNA damage in combination with hypoxia favored cell-cycle arrest rather than apoptosis. Analysis of gene expression revealed that in addition to activation of known p53 target genes such as p21 and gadd45, there was antagonism of c-MYC signaling, seen by downregulation of several known c-MYC target genes and the induction of Mxi1, a c-MYC antagonist (Corn and ElDeiry, 2007) . This illustrates how sensitive the balance is between growth arrest and apoptosis and the importance of the status of c-MYC.
It can be asked whether, for c-MYC overexpressing cells dependent on p53 for apoptosis, activation of p53 is sufficient or it is also necessary for c-MYC to regulate other components of the apoptotic pathway. In other words, is p53 necessary but not sufficient for p53-dependent MYC-mediated apoptosis? Two c-MYC mutant alleles found in human Burkitt's lymphoma were cloned into murine hematopoietic stem cells and then used to reconstitute the hematopoietic sytem of lethally irradiated recipient animals (Hemann et al., 2005) . Stem cells infected with wild-type c-MYC developed lymphoid tumors at low penetrance after a long latency, whereas recipients of stem cells infected with the mutant c-MYC genes developed the same lymphomas but at a significantly higher penetrance and reduced latency. BrdU incorporation showed that although there was increased proliferation in c-MYC overexpressing cells compared with control cells, there was no difference in proliferation between the mutants and the wild-type c-MYC. The impact of MYC expression on apoptosis was compared for wild-type and mutant MYC. Recipient mice were reconstituted with stem cells co-infected with retrovirus expressing c-MYC constructs and a retrovirus expressing the anti-apoptotic gene Bcl-2. Notably, when co-expressed with Bcl-2, wild-type and mutant MYC produced equally aggressive B-cell lymphomas (Hemann et al., 2005) . Thus, in the absence of apoptosis, wild-type and mutant c-MYC were equally oncogenic. In addition, cells expressing either wild-type or mutant c-MYC showed a similar increase in p53 phosphorylation and expression of the p53 transcriptional targets Bax, Puma and Noxa (Hemann et al., 2005) . The BH3-only protein Bim inhibits c-MYC-induced lymphomagenesis, and its expression is elevated in B cells overexpressing c-MYC (Egle et al., 2004) . Bim was induced in response to wild-type MYC in mouse embryonic fibroblasts (MEFs), FL5.12 cells and HSCs, as well as in p53-null MEFs, thereby demonstrating that Bim induction is not dependent on p53. Both MYC mutants were unable to induce Bim efficiently. In addition, Bim-null stem cells expressing wild-type MYC were as oncogenic as similar cells expressing either of the MYC mutants. As predicted, Bim expression was reduced in Burkitt's lymphomas expressing MYC mutants (Hemann et al., 2005) . Mutant c-MYC proteins retained their ability to stimulate proliferation and activate p53, but were defective at promoting apoptosis due to a failure to induce Bim and effectively inhibit Bcl-2 (Hemann et al., 2005) . These experiments demonstrate that the MYCmediated apoptotic response cannot be accomplished only by activating the p53 apoptotic program, but it also requires p53-independent signals.
MYC apoptosis independent of p53
The cross talk between c-MYC and P53 is important in regulating the decision of cells to undergo apoptosis in response to apoptotic stimuli, yet MYC-mediated apoptosis can also be p53 independent. Studies on the functional interaction between p53 and c-MYC have shown that c-MYC-mediated apoptosis is dependent on p53 in some cell types, but not in others (reviewed by Hoffman and Liebermann, 1998) . Ectopic expression of c-MYC does not induce apoptosis in serum-starved mouse MEFs from p53-null mice, whereas apoptosis occurs in similarly treated MEFs from wild-type mice. Enforced expression of MYC in 10.1Val5 cells, which contain a temperature-sensitive p53 transgene, revealed that only when p53 is active do the cells undergo MYCmediated apoptosis, and this p53 activity did not require induction of p53 target proteins. In lymphoid and myeloid cells, MYC-driven apoptosis is p53 independent, at least for the specifc cells and treatments investigated (Hsu et al., 1995; Hoffman and Liebermann, 1998) . Both p53-dependent and p53-independent mechanisms for c-MYC-induced apoptosis have been shown to exist in epithelial cells (Sakamuro et al., 1995) .
MYC amplifies apoptotic signaling at the mitochondria
Both cell culture-based findings and many different MYC transgenic mouse models have established an c-MYC in apoptosis and cancer B Hoffman and DA Liebermann important function in the apoptotic response for modulating the oncogenic potential of c-MYC. Furthermore, these studies have confirmed that the mitochondrial apoptotic pathway participates in MYC-mediated apoptosis. A large body of evidence exists showing that c-MYC can alter the balance of pro-and anti-apoptotic members of the Bcl-2 family, in parallel with or independent of p53, influencing the intrinsic apoptotic pathway.
Anti-apoptotic Bcl-2 proteins
The effect of Bcl-2 expression, as well as that of other anti-apoptotic Bcl-2 family members, on MYCmediated apoptosis was investigated shortly after it was shown that c-MYC could regulate apoptosis. Bcl-2 inhibits MYC-mediated apoptosis in some but not all cell systems, although having no effect on the proliferative function of c-MYC (Hoffman and Liebermann, 1998; Nilsson and Cleveland, 2003) . This interaction between c-MYC and Bcl-2 provided an explanation for the cooperation of MYC and Bcl-2 in cell transformation. BHRF1, an Epstein-Barr virus protein and a member of the Bcl-2 family, inhibits c-MYC-induced apoptosis that occurs in the absence of survival factors and, similar to Bcl-2, has no effect on growth promotion (Hoffman and Liebermann, 1998; Nilsson and Cleveland, 2003) . Similarly, Mcl-1, another Bcl-2 family gene, provides protection against MYC-mediated apoptosis (Hoffman and Liebermann, 1998; Nilsson and Cleveland, 2003) . Although ectopic expression of antiapoptotic gene products inhibited apoptosis, these experiments did not ask if their expression or function is inhibited when c-MYC promotes apoptosis.
Evidence that some anti-apoptotic Bcl-2 members are regulated by MYC independent of p53 was obtained using mouse models and primary cell cultures. In over half of lymphomas from Em-myc transgenic mice, Bcl-2 and/or Bcl-X(L) levels are markedly elevated; this elevation did not correlate with loss of ARF or p53 function in tumor cells, indicating that these two apoptotic pathways are inactivated independently (Eischen et al., 2001a) . In primary cultures of lymphoid cells from Em-myc transgenic mice, MYC activation suppresses Bcl-X(L) RNA and protein, and Bcl-X(L) and Bcl-2 expression are inhibited by MYC in precancerous B cells from these mice. That suppression of Bcl-X(L) RNA levels by MYC requires de novo protein synthesis indicates that repression is indirect (Eischen et al., 2001a) .
In IL-3-dependent immortal 32D.3 myeloid cells, the ARF/p53 apoptotic pathway is inactivated, as these cells fail to express ARF. Nonetheless, c-MYC overexpression accelerated apoptosis when these cells were deprived of IL-3 (Eischen et al., 2001b) . Furthermore, c-MYC overexpression suppresses Bcl-2 protein and RNA levels, and restoration of Bcl-2 protein blocks this accelerated apoptosis. Using immortal myeloid cells engineered to overexpress c-MYC DNA-binding mutants demonstrated that the DNA-binding activity of MYC is required to suppress Bcl-2 expression (Eischen et al., 2001b) . These results are consistent with observations using mouse models, revealing that the suppression of anti-apoptotic Bcl-2 in MYC-overexpressing cells occurs independently of the ARF/p53 pathway.
Further confirmation that MYC suppresses antiapoptotic Bcl-2 family members was illustrated using gamma-irradiation (IR) in conjunction with overexpressed MYC. Some tumors overexpressing MYC and harboring p53-inactivating mutations are responsive to gamma-IR therapy, as are p53-deficient MEFs, suggesting that c-MYC may sensitize cells to gamma-IR independent of p53. Also in Em-myc transgenic B cells in vivo, apoptosis is triggered by gamma-IR. These apoptotic responses are associated with the suppression of the anti-apoptotic regulators Bcl-2 and Bcl-X(L). However, in p53-null MEFs, only Bcl-X(L) expression was suppressed, and Bcl-X(L) overexpression blocked apoptosis (Maclean et al., 2003) .
As expected, cultured pre-neoplastic Em-myc/bcl-2 (À/À) mature B cells displayed accelerated apoptosis compared with Em-myc B cells. It is well established that MYC and Bcl-2 synergize in tumor development, particularly lymphomagenesis, yet ablation of endogenous Bcl-2 did not prevent or even delay development of Em-myc lymphomas (Kelly et al., 2007) . Thus, many other pro-surivival/anti-apoptotic switches besides Bcl-2 can override MYC-mediated apoptosis.
As described previously, c-MYC negatively regulates expression of some genes, including p21/CIP, by binding to and inhibiting the transcriptional activator Miz-1 (Wu et al., 2003) . Using short hairpin RNA-mediated knockdown of Miz-1 as well as the well-characterized MYC mutant V394D mutant P, which is defective for Miz-1 inactivation, revealed that the ability of c-MYC to induce apoptosis in primary diploid human fibroblasts in response to growth factor withdrawal required c-MYC to inactivate Miz-1 (Patel and McMahon, 2006) . Furthermore, Miz-1 was shown to activate the transcription of pro-apoptotic Bcl-2 (Patel and McMahon, 2007) . Repressing Bcl-2, using either short hairpin RNA or small-molecule inhibitors, restored the apoptotic potential of the c-MYC mutant that is defective for Miz-1 inhibition (Patel and McMahon, 2007) . Thus, the downregulation of anti-apoptotic Bcl-2, crucial for MYC-mediated apoptosis, is mediated by c-MYC inhibition of the transcriptional activator Miz-1.
Pro-apoptotic Bax and Bak
In addition to suppressing anti-apoptotic Bcl-2 family members, MYC overexpression also induces expression and/or activation of pro-apoptotic Bcl-2 proteins independent of p53 activation. Either Bax or Bak are required for activation of apoptosis through the mitochondria. Evidence is available for MYC functionally activating each of these proteins as well as transcriptionally activating Bax. Overexpression of c-MYC upregulates endogenous pro-apoptotic Bax mRNA and protein expression in human cells. c-MYC/Max heterodimers were shown to bind to canonical E-box elements located in the Bax promoter region, where analysis of Bax regulatory region mutants suggests both MYC-dependent activation as well as c-MYC in apoptosis and cancer B Hoffman and DA Liebermann relief of repression through distinct E-box elements. The results suggest that c-MYC is involved in transcriptional activation of the Bax gene (Mitchell et al., 2000) . In contrast, other studies showed that c-MYC activation exerts no detectable effects on Bax expression, localization or conformation, yet Bax-deficient fibroblasts are resistant to apoptosis. Susceptibility to c-MYC-induced apoptosis is restored in Bax-deficient cells not only by ectopic expression of Bax, but also by microinjection of a peptide comprising a minimal BH3 domain; however, no synergy is detected between the BH3 peptide and c-MYC in fibroblasts deficient in both Bax and Bak. Fibroblasts lacking Bak remain susceptible to c-MYC-induced apoptosis. In these studies, functional activation of Bax is downstream of MYC (Juin et al., 2002) . Further support for the importance of Bax, but not Bak, in MYC-mediated apoptosis was obtained using a switchable mouse model of MYC-induced apoptosis in pancreatic beta cells, where it was shown that c-MYC induces apoptosis in vivo exclusively through Bax (Dansen et al., 2006) . MYC appears to have an important function in Bax activation at several levels. When apoptosis is induced in cells stimulated by overexpressed c-MYC, in some cells, Bax expression is transcriptionally activated and the level of Bax protein is increased, and in other cells, Bax is functionally activated, often by means of BH3-only proteins. In cells lacking c-MYC, mitochondrial membrane permeabilization by Bax is blocked by changes in the mitochondria that prevent Bax oligomerization (Annis et al., 2005) . Recently, it was shown that, in human lung adenocarcinomas and osteosarcoma cells, following administration of cytotoxic drugs, c-MYC cooperates with caspase 2 in activating Bax. Caspase-2 paricipates in the integration of Bax into the outer mitochondrial membranes, whereas c-MYC functions in oligermerization of Bax after its integration (Cao et al., 2008) . However, these studies as well as others do not ascertain if c-MYC is directly participating in Bax activation or if c-MYC induces/activates other factors that are directly participating in Bax oligomerization.
Pro-apoptotic BH3-only family members
The pro-apoptotic BH3-only family members are also regulated by c-MYC. As mentioned previously, wild-type c-MYC can trigger apoptosis by inducing the proapoptotic BH-3 only member, Bim, which neutralizes Bcl-2. B lymphoid cells from Em-myc-transgenic mice have elevated Bim protein levels; when Em-myc-expressing B lymphoid cells are deficient in Bim, the cells are resistant to apoptosis by cytokine deprivation or antigen receptor cross-linking. Thus, Bim is induced by c-MYC in B cells and mediates apoptosis. Interestingly, inactivation of only one Bim allele was sufficient to accelerate MYCinduced development of tumors (Egle et al., 2004) .
Tumors arising in Bim( þ / þ )Em-myc mice are often mutated in the p19ARF/p53 pathway; however, the p19ARF/p53 pathway was unaffected in most Bimdeficient tumors (Egle et al., 2004) . MYC with point mutations, found in human Burkitt's lymphoma, that failed to induce Bim also promote murine lymphomas by escaping both wild-type p53 and p19ARF-mediated apoptosis (Hemann et al., 2005) . These findings are consistent with Bim reduction being an effective alternative to loss of p53 function in blocking apoptosis when c-MYC is overexpressed.
The effect of treatment of rat fibroblasts with the histone deacetylase inhibitor suberoylanilide hydroxamic acid is MYC-expression dependent, with elevated MYC causing the most apoptosis. It was shown that suberoylanilide hydroxamic acid causes apoptosis by inducing the expression of Bim, independent of MYC, but requires MYC to activate Bax by reducing the levels of anti-apoptotic Bcl-2/Bcl-xL (Jiang et al., 2007) .
The BH3-only protein Bid was found in cytoplasmic extracts from Rat1 fibroblasts expressing active c-MYC protein. It was co-purified with an activity capable of inducing cytochrome c release from isolated mouse liver mitochondria (Iaccarino et al., 2003) . NOXA, another BH3-only protein, can also be regulated by c-MYC under certain conditions. Proteasome inhibitors including bortezomib, anticancer agents that preferentially kill a wide range of tumor cells, promote a dramatic induction of the pro-apoptotic protein NOXA in a tumor cell-restricted manner. Induction of NOXA by the proteasome inhibitors was shown to depend on c-MYC (Nikiforov et al., 2007) . Both ChIP and reporter assays have validated the conserved c-MYC-binding sites found on the NOXA promoter. Furthermore, downregulation of the endogenous levels of c-MYC abrogated the induction of NOXA, whereas forced expression of c-MYC conferred normal cells with the ability to accumulate NOXA and subsequently activate cell death programs in response to proteasome inhibition (Nikiforov et al., 2007) .
In summary, overexpression of c-MYC alters both pro-and anti-apoptotic members of the Bcl-2 family of proteins, to amplify the mitochondrial apoptotic pathway (Figure 2 ). Which Bcl-2 members are altered is determined by the cell type, the particular biological setting and the apoptotic stimulus.
MYC promotes apoptosis through the death receptor pathways at multiple junctions c-MYC not only modulates the intrinsic apoptotic pathway, but also participates in the extrinsic pathways. Early on, c-MYC was shown to sensitize Rat1a cells to the CD95/Fas death signaling pathway and to act downstream of the CD95/Fas receptor (Hueber et al., 1997) . These investigations suggested that the function of c-MYC was due to amplification of the death signal at the mitochondria, but further experimentation has demonstrated that c-MYC also has a more direct function in modulating death receptor-mediated apoptosis, as well as survival pathways activated by death receptors.
Overexpression of c-MYC dramatically sensitizes cells to the apoptotic action of the death ligands tumor necrosis factor, CD95L and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). Receptor signaling and death-inducing signaling complex (DISC) formation can trigger either apoptotic or survival signals. In addition, for type II cells, the receptormediated apoptotic response conveys death signals through the mitochondrial apoptosis pathway. It has already been established that c-MYC can amplify mitochondrial-driven apoptosis. How c-MYC influences the death receptor pathway directly, how it impacts on the survival pathways activated by DISC formation and how death receptor signaling is coupled to the mitochondrial apoptosis pathway will be reviewed.
c-MYC represses some of the survival pathways associated with death receptor and DISC activation, and this can promote apoptosis. Death receptor signaling can activate the nuclear factor-kB (NF-kB) transcription factor, which suppresses receptor-induced apoptosis. c-MYC was shown to inhibit tumor necrosis factor receptor-induced activation of pro-survival c-Jun kinases and NF-kB (Klefstrom et al., 1997) . Using Baxnull human colon carcinoma cells that are resistant to TRAIL unless c-MYC is overexpressed, it was found that c-MYC interfered with TRAIL-induced expression of the anti-apoptotic Bcl-2 proteins Mcl-1 and cIAP2 by inactivating NF-kB (Ricci et al., 2007) , thereby promoting apoptosis. Thus, inhibition of the cell survival pathway can promote or enable the apoptotic response.
MYC can alter expression of several key players of the death receptor pathway, to promote activation of death receptor and the DISC. Reduced expression of Fas-associated death domain-like IL-1b-converting enzyme (FLIP), a casase-8 inhibitor, correlated with elevated levels of c-MYC expression in cell culture and in mouse models of c-MYC-induced tumorigenesis (Ricci et al., 2004) . Using both chromatin immunoprecipitation and luciferase reporter analyses, c-MYC was shown to repress FLIP transcription, causing increased caspase-8 activation (Ricci et al., 2004) . MYC can upregulate expression of the TRAIL receptor DR5 at the cell surface (Wang et al., 2004) . Furthermore, c-MYC has also been shown to transcriptionally induce expression of FasL (Amanullah et al., 2002; Brunner et al., 2000; Kasibhatla et al., 2000) .
Many cells that respond to death receptor signaling are type II cells, conveying death receptor signaling through the intrinsic mitochondrial pathway. Death receptor ligands activate multiple signaling routes in cells. Overexpressed c-MYC inhibits survival signals, resulting in apoptosis if the apoptotic signaling is sufficiently strong. MYC can enhance receptor signaling and also amplify the death signal at the mitochondria (Figure 3 ). In addition, effector caspases have been shown to activate caspase-8 by the so-called 'caspase feedback amplification loop' (Adrain and Martin, 2006; Lakhani et al., 2006; Nieminen et al., 2007a) , where downstream caspases activate earlier events such as activator caspases and Bax. In the case of TRAIL signaling, it was shown that c-MYC controls the feedback amplification loop, resulting in mitochondrial amplification of the caspase-8-Bid signals (Nieminen et al., 2007a, b) . c-MYC enhanced caspase-8 activation of cells with soluble TRAIL and, using chemically dimerizable caspase-8, revealed that this enhancement did not involve receptor-activated DISC (Nieminen et al., 2007a, b) . Furthermore, anti-apoptotic Bcl-X(L) was shown to have no effect on cleavage of caspase-8 by TRAIL, yet it abolished the augmented caspase-8 cleavage by c-MYC (Nieminen et al., 2007a, b) . These finding argue that the augmented cleavage of caspase-8 is due to downstream caspases from c-MYC-primed mitochondria (Nieminen et al., 2007a, b) . How c-MYC primes the mitochondria through Bak activation and what the ramifications are for this mitochondriapriming model are discussed elsewhere (Nieminen et al., 2007a, b) . MYC can clearly influence death receptor-induced apoptosis at many junctions to determine the ultimate outcome (Figure 3 ).
Deregulated c-MYC prematurely triggers the normal apoptotic response associated with terminal myeloid differentiation
Hematopoiesis is a profound example of cell homeostasis that is regulated throughout life. Most hematopoietic cells are short-lived, with apoptosis as the final step in their development; alterations in this apoptotic response can promote either leukemias by blocking apoptosis or anemias by excessive apoptosis. The proto- c-MYC in apoptosis and cancer B Hoffman and DA Liebermann oncogene c-MYC is one of many genes that participate in regulating hematopoietic homeostasis, such that deregulating its expression has profound effects. Consistent with this, c-MYC has been implicated in the etiology of a wide variety of hematologic malignancies. The oncogenic impact of c-MYC is enhanced by various mechanisms that suppress its apoptotic response Hemann et al., 2005; Eischen et al., 2001a) . Thus, apoptosis associated with deregulated/overexpressed c-MYC is a failsafe mechanism that restrains tumor promotion when c-MYC expression is deregulated.
The murine M1 myeloid leukemic cell line, which is p53 negative, proliferates autonomously and can be induced with the physiological inducer IL-6. We have observed that deregulated c-MYC expression in M1 cells blocks IL-6-induced differentiation at an intermediate stage; the cells fail to exit the cell cycle, proliferating indefinitely, with a portion of the cells undergoing apoptotic cell death by prematurely recruiting both the types I and II CD95/Fas apoptotic pathway (Amanullah et al., 2000; Amanullah et al., 2002; Hoffman et al., 2002) . Similar results were also observed in normal myeloid cells from bone marrow (Amanullah et al., 2000; Amanullah et al., 2002) . There is evidence to suggest that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal myeloid differentiation program, and that deregulated c-MYC expression prematurely triggers this signaling pathway (Amanullah et al., 2002; Hoffman et al., 2002) .
Interleukin-6-mediated induction of myeloid differentiation resulted in rapid cell-surface expression of CD95 receptor and concomitant downregulation of CD95 ligand. Deregulated expression of c-MYC prevented the downregulation of CD95 ligand and caused premature and incomplete downregulation of c-FLIP (Amanullah et al., 2002) , accounting for the c-MYC-mediated apoptosis. In addition to all the hallmarks of apoptosis, cytochrome C was released into the cytosolic fraction. MYC has been shown to transactivate the CD95L gene (Amanullah et al., 2002; Brunner et al., 2000; Kasibhatla et al., 2000) , as well as to downregulate FLIP (Ricci et al., 2004) . The MYC-mediated apoptotic response requires activation of the DISC, as apoptosis is blocked by constitutive FLIP expression (Amanullah et al., 2002) . Constitutive expression of the anti-apoptotic Bcl-2 gene in M1myc cell variants delayed the onset of apoptosis, which was not accompanied by cytochrome C release from the mitochondria. Thus, first the type II (mitochondriadependent) and then the type 1 CD95/Fas apoptotic pathways were activated (Amanullah et al., 2002) , and the type 1-mediated apoptotic response does not require feedback from the intrinsic pathway to successfully complete the death process. In contrast, Bcl-2 expression in type II cells protects cells from apoptosis following FasL stimulation, and using these cells it has been shown that NF-kB is activated (Kreuz et al., 2004) .
Deregulated expression of both conditional mycER and mycER variants blocked terminal myeloid differentiation but failed to induce the apoptotic response associated with RIP kinases, originally identified as a death domaincontaining Fas-interacting protein, have been described as regulators at the crossroad of a cell's decision to survive or die; not only are pro-survival responses triggered by these kinases, but also death-inducing programs (Meylan and Tschopp, 2005; Festjens et al., 2007) . RIP has been shown to be essential for Fasinduced NF-kB activation (Kreuz et al., 2004) , and it has also been suggested that receptor interacting protein (RIP) is not part of the Fas DISC. RIP1 has been reported to activate NF-kB, which can activate Akt, and both of these can induce the pro-survival Mcl-1 gene (Meng et al., 2002; Schulze-Bergkamen et al., 2004; Francois et al., 2005; Kobayashi et al., 2005; Meylan and Tschopp, 2005; Festjens et al., 2007) . With the exception of M1 cells, RIP has not been reported to participate in Fas receptor-mediated apoptotic cell death, but rather in survival and necrosis. The data for M1 cells are consistent with RIP1-promoting apoptosis when there is engagement of the Fas receptor with its ligand, and there is no evidence that RIP1 is involved in activation of NF-kB in IL-6-treated M1 cells.
In M1myc cells, the Fas/CD95 death receptor pathway is switched on, whereas in M1 cells, it is off due to both lack of CD95 ligand and elevated cFLIP. Although RIP1 is expressed, it is unclear what affect it can have without engagement of Fas receptor with its ligand. The observed activation of NF-kB and Akt in IL-6-treated M1 and M1mycER cells can be accounted for by IL-6 treatment, as the differentiation inducer is a survival factor shown to activate Akt, including in M1 cells, and to induce Mcl-1 (Kobayashi et al., 2005; Lindemans et al., 2006; Cavarretta et al., 2007; Vesely et al., 2007) .
c-MYC can block the activation of NF-kB (Ricci et al., 2007) , thus constitutive wild-type c-MYC can c-MYC in apoptosis and cancer B Hoffman and DA Liebermann transactivate RIP and concomitantly prevent IL-6-mediated and RIP-mediated induction of Mcl-1. In contrast, in IL-6 þ 4-OHT-treated M1mycER cells, RIP1 is not induced, NF-kB and Akt activation are not blocked, and induction of Mcl-1 is high. If c-MYC blocks NF-kB activation, it is surprising that mycER cannot accomplish this as well.
Constitutive RIP1 expression in M1mycERtRIP1 cells treated with IL-6 þ 4-OHT results in rapid apoptosis, and neither induction of Mcl-1 nor activation of NF-kB and Akt. In these M1mycERtRIP1 cells, similar to M1myc cells and in contrast to M1 cells, the Fas/ CD95 death receptor pathway is engaged, thereby elevated RIP1 expression tilts the balance from survival to death. Mechanistically, it is not yet understood how these different molecular regulators of death and survival are interacting in this biological system.
Wild-type c-MYC expression in myeloid cells blocks differentiation and promotes an incompletely penetrant apoptotic response; this balance is shifted to survival when MycER is expressed in myeloid cells by altering the level of pro-and anti-apoptotic players. In addition to CD95L and cFLIP, previously described components of the life-death decision regulated not only by c-MYC, but also by RIP1, NF-kB, Akt and Mcl-1, and their regulation is differentially influenced by the MycER variant compared with c-MYC. What is clear is that altering c-MYC or its downstream effectors can influence the balance between apoptosis and survival, and ultimately the oncogenic potential of the c-MYC oncogene. This knowledge can be exploited to manipulate the downstream effectors, such as by elevating RIP1, to promote apoptosis and drive the death of cancer cells.
It appears, then, that in myeloid cells, the CD95/Fas apoptotic pathway functions in at least two ways to maintain homeostatic cell numbers. First, it contributes to the elimination of differentiated myeloid cells at the end of their useful lifespan. And second, in the presence of inappropriately expressed positive regulators of proliferation/negative regulators of differentiation such as c-MYC, cells become sensitized to CD95/Fasmediated apoptosis, thereby facilitating the destruction of these cells. Undifferentiated myeloid cells that continue to proliferate can acquire additional mutations, resulting in progression to a leukemic phenotype. These proposed functions are consistent with a function of CD95/Fas, or any other genes regulating the CD95/Fas pathway, as tumor suppressors. Specific downstream effectors of c-MYC that modulate apoptosis can be used as therapeutic targets to drive the death of tumor cells.
Conclusions
Understanding how the fate of a cell to survive or die is determined is important to understanding normal development, as well as disease states of either excessive growth or death. c-MYC is a major player in these decisions. Although a huge amount of information has accumulated, and our understanding of apoptosis and the function of c-MYC in apoptosis have increased orders of magnitude in the past 15 years, there is still a gap in understanding how the different apoptotic regulatory loops are integrated to ultimately decide the fate of a cell. MYC regulates expression of more than 15% of all genes, and which of these targets are relevant for the function of MYC in apoptosis is not known and would have to be clarified with gain-and loss-of-function studies. Yet MYC target genes alone will not explain the influence of MYC on a cell. Clearly, the biological status of the cell will influence the outcome of MYC overexpression, and may also participate in determining which MYC target genes are expressed/repressed. Also, the importance of MicroRNAs is starting to emerge. Deciphering how overexpression of c-MYC interfaces with the apoptotic regulatory loops is important to understand how tumors arise, and information on these pathways and molecular targets that regulate them can be exploited to enhance our capabilities to design rational therapeutic regimens to treat specific tumors.
